Home
ABOUT US
Overview
Business Model
Board of Directors
Management Team
History & Milestones
Sustainability
R & D PIPELINE
INVESTORS
Investor Overview
Financial Reports
Shareholders’ Meetings
Events & Presentations
NEWS
CAREERS
CONTACT
EN
中文版
NEW DRUGS FOR THE TREATMENT OF CANCER
PharmaEngine
We Race With You
DISCOVER MORE
CANCER TREATMENT PRODUCTS
ONIVYDE
A Revolutionary Durg
DISCOVER ONIVYDE
History
&
Milestones
Onivyde
PEP07: A novel, brain penetrant oral Chk1 inhibitor for the treatment of AML and MCL (6th Annual DDR Inhibitors Summit 2023)
2023/1/25
Onivyde® regimen (NALIRIFOX) demonstrated statistically significant improvement in overall survival in 1L PDAC(Supplementary information)
2023/1/21
Positive Topline Results from Phase III NAPOLI-3 trial of ONIVYDE® regimen (NALIRIFOX) as a first-line treatment for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
2022/11/9
PEP07
R&D Pipeline
Events & Presentations
Organization
Our Partners
Contact Us
Go To Top